Alpha Teknova Revenue Rises 22% as 2026 Outlook Reaches $48 Million

Alpha Teknova's third-quarter revenue climbed 22% year over year to $12.7 million, while the company raised its 2026 revenue outlook to $46 million to $48 million.

The final revenue figure was at the top of the company's preliminary range of $12.5 million to $12.7 million, disclosed alongside its earlier $40 million stock offering.

Net loss narrowed to $3.5 million for the quarter ended Sept. 30, from $4.3 million in the same period a year earlier. The loss was $0.06 per diluted share.

Alpha Teknova makes critical reagents for life sciences applications, including therapies, vaccines and molecular diagnostics.